2015 NCS/SCCM声明：颅内出血逆转抗血栓生成指南

Antithrombotics, including anticoagulants, antiplatelet agents, and thrombolytics are used to treat or decrease the risk of thrombotic or embolic events in a wide variety of medical conditions. With the introduction of new antithrombotics to the market, an aging patient population, and the increasing prevalence of atrial fibrillation, the use of antithrombotics is expected to continue to rise in future years [1, 2]. As compared to patients experiencing spontaneous intracranial hemorrhage without anticoagulation, those on antithrombotics have a higher likelihood of secondary hematoma expansion, and an increased risk of death, or poor functional outcome [3–5]. Because of the controversial literature regarding the optimal antithrombotic reversal strategies in patients with intracranial hemorrhage, the Neurocritical Care Society/ Society of Critical Care Medicine Antithrombotic Reversal in Intracranial Hemorrhage Guideline Writing Committee was established in October 2012. Its aim was to develop evidence-based guidelines for counteracting the effects of commonly available antithrombotic agents in the setting of intracranial hemorrhage.